Correlation between serum free fatty acid and cardiac function in patients with acute heart failure

doi:10.3969/j.issn.1004-583X.2021.03.003

Abstract

Abstract:

Objective To explore the correlations between serum free fatty acid(FFA) and cardiac function in patients with acute heart failure(AHF). Methods One hundred and sity three patients with AHF were divided into the LVEF<40% group and LVEF≥50% group basics on left ventricular ejection fraction(LVEF). FFA, N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin I(cTnI)and other related indicators were detected when admission. Indicators including the left ventricular ejection fraction(LVEF), LVEF fraction shortening(FS), left ventricular end-diastolic diameter(LVEDD), eft ventricular end-systolic dimension(LVESD) and TEi index were recorded. Results FFA, NT-proBNP and cTnI in LVEF<40% group was significantly higher than such indexes in LVEF≥50% group (P<0.05). FFA, NT-proBNP and cTnI were risk factors for LVEF<40% in AHF patients. The predicted AUC of FFA and NT-proBNP for patients with LVEF<40% were 0.856 and 0.810 respectively. In AHF patients, the cardiac function of high FFA group was significantly lower than that of low FFA group (P<0.05). Conclusion FFA, NT-proBNP and cTnI are the risk factors of LVEF < 40% in patients with AHF. FFA has certain predictive value for predicting the deterioration of patients' heart function among of these.

Key words: heart failure, fatty acid, left ventricular ejection fraction

CLC Number:

R541.6

Bai Lian, Guo Peng, Luan Bo, Bai Hao, Jiang Shan. Correlation between serum free fatty acid and cardiac function in patients with acute heart failure[J]. Clinical Focus, 2021, 36(3): 208-211.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.03.003

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I3/208

Figures/Tables 5

References 19

[1]	Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure[J]. Eur J Heart Fail, 2020,22(8):1342-1356. doi: 10.1002/ejhf.v22.8 URL
[2]	Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail, 2017,23(8):628-651. doi: 10.1016/j.cardfail.2017.04.014 URL
[3]	Shahid I, Kumar P, Khan MS, et al. Deaths from heart failure and cancer: location trends[J]. BMJ Support Palliat Care, 2020, 22:bmjspcare-2020-002275.
[4]	Liu M, Galli G, Wang Y, et al. Novel therapeutic targets for hypoxia-related cardiovascular diseases: the role of HIF-1[J]. Front Physiol, 2020,11:774. doi: 10.3389/fphys.2020.00774 URL
[5]	Billingsley H, Canada JM, Markley R, et al. Abstract p436: the role of free fatty acids in patients with obesity and heart failure with preserved ejection fraction: a post-hoc analysis of the ufa-preserved pilot study[J]. Circulation, 2020,141.
[6]	Zhu N, Jiang W, Wang Y, et al. Plasma levels of free fatty acid differ in patients with left ventricular preserved, mid-range, and reduced ejection fraction[J]. BMC Cardiovasc Disord, 2018,18(1):104. doi: 10.1186/s12872-018-0850-0 URL
[7]	Degoricija V, Trbušić M, Potočnjak I, et al. Serum concentrations of free fatty acids are associated with 3-month mortality in acute heart failure patients[J]. Clin Chem Lab Med, 2019,57(11):1799-1804. doi: 10.1515/cclm-2019-0037 pmid: WOS:000489114100027
[8]	崔炜, 刘德敏, 耿雪, 等. 2018年心血管病学重要临床进展[J]. 临床荟萃, 2019,34(1):11-16.
[9]	王华, 梁延春. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018,46(10):760-789.
[10]	Flatt WP. Energy metabolism[J]. J Assoc Off Anal Chem, 2020, (5):5.
[11]	Fragasso G. Deranged cardiac metabolism and the pathogenesis of heart failure[J]. Card Fail Rev, 2016,2(1):8-13. doi: 10.15420/cfr.2016:5:2 URL
[12]	Shiga T, Suzuki A, Haruta S, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid-range, and reduced ejection fractions in Japan[J]. ESC Heart Fail, 2019,6(3):475-486.
[13]	Shue H, Gregory S. Plasma oleic-to-stearic acid ratio and future heart failure risk: from MESA[J]. Curr Dev Nutr, 2020, (Supplement_2): Supplement_2.
[14]	Voros G, Ector J, Garweg C, et al. Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling[J]. Circ Heart Fail, 2018,11(12):e004953.
[15]	Bertero E, Maack C. Reply to 'Metabolic remodelling in heart failure revisited'[J]. Nat Rev Cardiol, 2018,15(12):780-781.
[16]	Bertero E, Maack C. Metabolic remodelling in heart failure[J]. Nat Rev Cardiol, 2018,15(8):457-470. doi: 10.1038/s41569-018-0044-6 URL
[17]	Cetrullo S, D'Adamo S, Panichi V, et al. Modulation of fatty acid-related genes in the response of h9c2 cardiac cells to palmitate and n-3 polyunsaturated fatty acids[J]. Cells, 2020,9(3):537. doi: 10.3390/cells9030537 URL
[18]	Sahraoui A, Dewachter C, Vegh G, et al. High fat diet altered cardiac metabolic gene profile in Psammomys obesus gerbils[J]. Lipids Health Dis, 2020,19(1):123. doi: 10.1186/s12944-020-01301-y URL
[19]	马莉, 李晓惠, 陶凌, 等. 血清肌钙蛋白Ⅰ对充血性心力衰竭预后的影响[J]. 临床荟萃, 2010,25(11):927-929.

组别	例数	性别(例)		年龄 (岁)	BMI (kg/m²)	病史(例)
组别	例数	男	女	年龄 (岁)	BMI (kg/m²)	吸烟史	饮酒史	糖尿病	高血压	房颤史	心肌梗死史	PCI术后
LVEFF<40%组	83	55	28	69.1±4.65	23.73±3.07	36	33	37	32	37	32	25
LVEF≥50%组	80	42	38	68.8±4.42	24.52±4.05	36	39	39	33	27	26	20
统计值		χ²=0.042		t=0.095	t=1.090	χ²=0.174	χ²=0.346	χ²=0.932	χ²=0.673	χ²=0.172	χ²=0.642	χ²=0.163
P值		0.13		0.49	0.06	0.96	0.34	0.82	0.88	0.35	0.46	0.68

组别	例数	性别(例)		年龄 (岁)	BMI (kg/m²)	病史(例)
组别	例数	男	女	年龄 (岁)	BMI (kg/m²)	吸烟史	饮酒史	糖尿病	高血压	房颤史	心肌梗死史	PCI术后
LVEFF<40%组	83	55	28	69.1±4.65	23.73±3.07	36	33	37	32	37	32	25
LVEF≥50%组	80	42	38	68.8±4.42	24.52±4.05	36	39	39	33	27	26	20
统计值		χ²=0.042		t=0.095	t=1.090	χ²=0.174	χ²=0.346	χ²=0.932	χ²=0.673	χ²=0.172	χ²=0.642	χ²=0.163
P值		0.13		0.49	0.06	0.96	0.34	0.82	0.88	0.35	0.46	0.68

组别	例数	cTnI(ng/ml)	Scr(μmol/L)	TG(mmol/L)	FFA(μmol/L)	NT-proBNP(pg/ml)
LVEFF<40%组	83	0.22(0.58)	87.00(66.90)	1.46(0.90)	666.27(219.48)	4267.00(3444.00)
LVEF≥50%组	80	0.14(0.39)	127.00(98.65)	1.38(0.64)	454.96(124.63)	2916.00(1317.50)
Z值		2.221	1.720	0.252	7.854	7.878
P值		0.026	0.086	0.801	0.000	0.000

组别	例数	cTnI(ng/ml)	Scr(μmol/L)	TG(mmol/L)	FFA(μmol/L)	NT-proBNP(pg/ml)
LVEFF<40%组	83	0.22(0.58)	87.00(66.90)	1.46(0.90)	666.27(219.48)	4267.00(3444.00)
LVEF≥50%组	80	0.14(0.39)	127.00(98.65)	1.38(0.64)	454.96(124.63)	2916.00(1317.50)
Z值		2.221	1.720	0.252	7.854	7.878
P值		0.026	0.086	0.801	0.000	0.000

变量	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
变量	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
CTnI(ng/ml)	1.065	0.443	5.768	0.016	2.901	1.216	6.918
FFA(μmol/L)	0.005	0.002	7.206	0.007	1.006	1.001	1.010
NT-proBNP(pg/ml)	0.001	0.000	12.878	0.000	1.001	1.001	1.002
常量	-7.239	1.214	33.546	0.000	0.001